Lyvispah is a drug owned by Amneal Pharmaceuticals Llc. It is protected by 5 US drug patents filed from 2021 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 29, 2041. Details of Lyvispah's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11491125 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(16 years from now) | Active |
| US11850225 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(16 years from now) | Active |
| US10792262 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(14 years from now) | Active |
| US11654124 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(14 years from now) | Active |
| US11931328 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lyvispah's patents.
Latest Legal Activities on Lyvispah's Patents
Given below is the list of recent legal activities going on the following patents of Lyvispah.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eCertificate of Correction | 14 May, 2024 | US11850225 |
| Patent eCofC Notification | 14 May, 2024 | US11850225 |
| Email Notification Critical | 14 May, 2024 | US11850225 |
| Mail Patent eCofC Notification | 14 May, 2024 | US11850225 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Apr, 2024 | US10792262 |
| Mail Patent eGrant Notification | 19 Mar, 2024 | US11931328 |
| Patent eGrant Notification | 19 Mar, 2024 | US11931328 |
| Email Notification Critical | 19 Mar, 2024 | US11931328 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Mar, 2024 | US11931328 |
| Recordation of Patent eGrant | 19 Mar, 2024 | US11931328 |
US patents provide insights into the exclusivity only within the United States, but Lyvispah is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lyvispah's family patents as well as insights into ongoing legal events on those patents.
Lyvispah's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lyvispah's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 29, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lyvispah Generic API suppliers:
Baclofen is the generic name for the brand Lyvispah. 33 different companies have already filed for the generic of Lyvispah, with Rubicon having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lyvispah's generic
Alternative Brands for Lyvispah
Lyvispah which is used for treating spasticity in conditions like multiple sclerosis and spinal cord injuries., has several other brand drugs using the same active ingredient (Baclofen). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Baclofen, Lyvispah's active ingredient. Check the complete list of approved generic manufacturers for Lyvispah
About Lyvispah
Lyvispah is a drug owned by Amneal Pharmaceuticals Llc. It is used for treating spasticity in conditions like multiple sclerosis and spinal cord injuries. Lyvispah uses Baclofen as an active ingredient. Lyvispah was launched by Amneal in 2021.
Approval Date:
Lyvispah was approved by FDA for market use on 22 November, 2021.
Active Ingredient:
Lyvispah uses Baclofen as the active ingredient. Check out other Drugs and Companies using Baclofen ingredient
Treatment:
Lyvispah is used for treating spasticity in conditions like multiple sclerosis and spinal cord injuries.
Dosage:
Lyvispah is available in granules form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/PACKET | GRANULES | Prescription | ORAL |
| 20MG/PACKET | GRANULES | Prescription | ORAL |
| 10MG/PACKET | GRANULES | Prescription | ORAL |